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ABSTRACT 
Ego3, a regulator of TORC1 signaling, is degraded by the  
intralumenal fragment pathway 
Qiao Jin 
Target of rapamycin complex 1 (TORC1) is a conserved protein kinase complex whose activity 
controls metabolism in eukaryotic cells.  To function, TORC1 and its regulators are localized to 
lysosome membranes. The mechanism(s) that control TOR complex protein lifetimes remain 
enigmatic. The IntraLumenal Fragment (ILF) pathway is a selective protein degradation pathway 
that involves lysosomes. Thus, I hypothesized that components of TORC1, EGO and SEA 
complexes may be degraded by this ILF pathway.  
Using the yeast S. cerevisiae and its vacuolar lysosome (or vacuole) as models, I tested 
this hypothesis by first imaging live cells by fluorescence microscopy. I found that several 
subunits of TORC1, EGO and SEA complexes tagged with GFP are sorted into boundaries 
between docked vacuoles and accumulate within the vacuole lumen. However, when I isolated 
vacuoles from cells and repeated this experiment in vitro, I found that nearly all components re-
localized to endosomes. The only exception was Ego3, a subunit that tethers the EGO complex 
to vacuole membranes. I then applied rapamycin, an inhibitor of TOR, to induce TOR protein 
downregulation and degradation. In vivo, I found that rapamycin stimulated sorting of TOR 
complex . Whereas, in vitro, rapamycin only enhanced sorting, internalization and degradation of 
Ego3.  
In conclusion, many components of TOR signaling complexes seem to be degraded by 
the ILF pathway including Ego3. Thus, I speculate that the ILF pathway may play an important 
role in downregulating TOR activity. 
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In all organisms, from yeast to humans, aging represents the accumulation of physical and 
physiological changes of an individual over time (Bowen et al., 2004). In humans, aging is 
among the largest risk factors for disease (Holroyd et al., 2008; Christensen et al, 2009; Dilling 
et al., 2014). Researchers have been investigating the molecular basis of aging for decades, and 
the underlying mechanisms are beginning to be revealed, although its cause and valid strategies 
to prevent this process are still largely unknown. At the cellular level, aging is promoted by an 
accumulation of damage overtime within the cell, ultimately leading to dysfunction and cell 
death.  Currently, one of the most widely accepted aging theory involves the target of rapamycin 
(TOR) pathway, mainly target of rapamycin complex one (TORC1), a key regulator of cellular 
metabolism (Evans et al., 2011; McCormick et al., 2011). This theory involves the regulation of 
autophagy by TORC1. When TORC1 is active, its inhibition of autophagy leads an accumulation 
of toxic materials such as protein aggregates and damaged organelles therefore causes cell death 
(Budanov et al., 2010). Since TORC1 is an important player in aging, the study of its degradation, 
and proteins that regulate its activity, may give us an insight into the mechanism by which the 
cell downregulates TORC1 signaling therefore impacting the cellular aging program.   
 
Target of Rapamycin Complex 1(TORC1) and Aging 
TORC1 is a highly conserved signaling complex found in all eukaryotic species from yeast to 
humans. It functions as a mediator between external stimuli such as caloric input and cell growth 
and proliferation (Kim et al., 2002; Hay and Sonenberg, 2004; Gonzalez and Rallis, 2017). To be 
activated, all components of TORC1 must assemble into a functional complex on lysosome (or 
vacuole in yeast) membranes. In term of acidic digestive compartments, the yeast vacuole and 
the lysosome are analogous. They also both recycle degradation products to replenish cellular 
storage. However, unlike lysosome, the vacuole serves as a storage of nutrients such as amino 




It has been shown that when TORC1 is inhibited, the lifespan of several eukaryotic 
organisms is extended (Fabrizio et al., 2001; Harrison et al., 2009; Robida-Stubbs et al., 2012). 
For example, blocking TOR signaling extends lifespan in yeast, worms, flies and mice. 
Importantly, rapamycin, a TORC1 inhibitor, prevents age-related diseases and extends lifespan 
even in old mice. Rapamycin also delays decline in cognitive function if administered starting at 
a young age in mice. Caloric restriction is another way that can extend lifespan. Caloric 
restriction prolongs lifespan in yeast, worms, flies, rodents, and possibly primates. The life-
prolonging effects of caloric restriction has been shown to be largely due to inhibition of TOR, 
as suggested by the findings that TORC1 inhibition mimics starvation and caloric restriction 
does not extend lifespan in yeast and flies if TORC1 signaling is defective (Hansen et al., 2007; 
Power et al., 2006) Moreover, knocking out S6K (ribosomal S6 kinase), a downstream substrate 
of TORC1, in mice correlates with extended life span and gives a similar phenotype to mice on 
calorie restricted diets (Selman et al., 2009). Whereas S6K overexpression renders D. 
melanogaster resistant to lifespan extension by rapamycin (Kapahi et al., 2009)  
 
4E-BP (eukaryotic translation initiation factor 4E-binfding protein) is the other important 
downstream target of TORC1, that is also thought to play a role in lifespan extension (Zid et al., 
2009). When phosphorylated by TORC1, 4E-BP dissociates from the translation machinery 
halting protein translation. Reduced protein synthesis has also been shown to extend lifespan in 
many species (Arnsburg et al., 2014). When not phosphorylated by TORC1, 4E-BP activates 
stress responsive genes, such as the tumor suppressor FoxO. These stress genes can exert a 
positive effect on lifespan by protecting cells and tissues from age-related damage, through 
transcriptional programs (Giannakou et al., 2008). For example, FoxO activates expression of 
glutamine synthetase (GS) and increased GS expression then inhibits TORC1 activity, 
representing a negative feedback loop. Furthermore, FoxO inhibits TORC1 signaling by 
inducing sestrins express which leads to activation of AMPK, a negative regulator of TORC1 
signaling (Tettweiler et al., 2005). In all, it is clear that TORC1 inhibition leads to lifespan 
extension. Thus, it is of interest to identify the cellular processes that downregulate (or degrade) 




Components of TORC1 singling in S. cerevisiae   
In S.cerevisiae, TORC1 is composed of the serine/threonine protein kinase Tor1 or Tor2 bound 
to Kog1, Tco89, and Lst8. All of these components have mammalian orthologs except Tco89 
(Loewith et al., 2002). Lst8 is a 36 kDa protein that has WD40 repeats and binds to the kinase 
domain of Tor1. Although its precise function is not fully understood, knockdown studies in 
mammals and yeast suggest that Lst8 also stimulates TORC1 signaling (Loewith et al., 2002; 
Chen and Kaiser, 2003; Kim et al., 2003). Kog1 (or Raptor in mammals), a seven WD-40 repeat 
and quadruple HEAT domain containing protein, is the largest component of TORC1 at 150 kDa. 
When Kog1/Raptor is knocked down in mammalian, worm, or fly cells, the phenotype mimics 
treatment with the TORC1 inhibitor rapamycin or depletion of Tor1 suggesting that Raptor 
stimulates mTOR signaling (Hara et al., 2002; Kim et al., 2002; Sarbassov et al., 2004). 
Kog1/Raptor interacts with Tor1 and its substrates S6K1 (ribosomal protein S6 kinase 1) and 
4EBP1 (eukaryotic initiation factor 4E binding protein 1). In turn, TORC1-mediated 
phosphorylation of 4EBP1, for example, stimulates downstream protein synthesis by inducing 
the release of 4EBP1 from eIF4E, allowing it to associate with other factors that drive cap-
dependent translation to support cell growth (Kim et al., 2002; Foster et al., 2010). Tco89, 
although has no mammalian orthologs, is an important regulatory subunit of TORC1 in yeast. It 
mediates the control of the Exit from G0 complex (EGOC) of TORC1 (Loewith and Hall, 2011).  
 
Upstream of TORC1, there are four major stimuli thought to be integrated by this 
signaling complex: growth factors, energy status, stress and nutrient availability. The 
mechanisms of involving the former three stimuli implicate the phosphatidylinositol 3-kinase 
(PI3K), Akt, TSC1/TSC2 and Rheb, a guanosine triphosphate (GTP)-binding protein in upstream 
signaling (Sarbassov et al., 2005). Nutrient availability, especially amino acids levels, on the 
other hand, involves stimulation of Rag GTPases (e.g. RagA – D in mammals) that activate 
TORC1 on lysosome membranes (Kim et al., 2008).    
 
Specifically, amino acids are sensed upstream of the EGO complex (EGOC, orthologus 
Ragulator in mammals) which consists of Gtr1 (orthologous to RagA and RagB), Gtr2 
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(orthologous to RagC and RagD), Ego1 and Ego3 in S. cerevisiae, whereby Ego1 and Ego3 are 
membrane associated proteins that serve as important components of EGOC for its localization 
to the vacuole membranes for TORC1 stimulation (Binda et al., 2009). For example, the 
presence of amino acids promotes GTP-binding to Gtr1, mediated by the guanine exchange 
factor (GEF) Vps39, and GTP hydrolysis of Gtr2, rendering Gtr2::GDP, which together activate 
TORC1 (Binda et al., 2009). Conversely, activation of Gtr1 GTPase activity rendering 
Gtr1::GDP terminates TORC1 signaling. This is mediated by the two SEA complexes: SEACIT, 
containing Iml1, Npr2 and Npr3 subunits, acts the GTPase activating protein (GAP) for Gtr1 to 
inhibit TORC1 signaling, whereas SEACAT (containing Sea2, Sea3, Sea4, Sec13 and Seh1 
subunits) inhibits SEACIT GAP activity, thus positively regulating TORC1 (Algret et al., 2014). 
Thus, I reasoned that altering the protein lifetimes of subunits with any of these four protein 
complexes, SEACAT, SEACIT, EGOC and TORC1, should influence TOR signaling.  But 
currently it is unclear how TOR signaling proteins are degraded in all eukaryotic cells. 
 
The ILF pathway and selective degradation of lysosome membrane proteins 
Although the function of TORC1 and its regulatory protein complexes has been well studied, 
how components are degraded or downregulated is unknown. Ubiquitin Proteasome Pathway 
(UPP) is a well-conserved process in eukaryotic organisms responsible for selective degradation 
of soluble, cytoplasmic proteins (Hasselgren et al., 1997). Upon stimulation (e.g. 
phosphorylation or misfolding), a client protein is labeled with ubiquitin, a highly conserved and 
ubiquitously expressed small protein composed of 76 amino acids. Protein labeling involves 
three important enyzmes: the ubiquitin activating enzyme or E1 enzyme, the ubiquitin 
conjugating enzyme or E2 enzyme, and the ubiquitin ligase or E3 ligase. Ubiquitin-tagged client 
proteins are sorted into and degraded by the 26S proteasome, a large cylindrical multi-enzyme 
complex within the cytoplasm (Tu et al., 2012). However, the proteasome is primarily 
responsible for degradation of soluble, cytosolic proteins, not membrane-associated proteins, like 
many of the subunits of TORC1 and its regulatory complexes (Tu et al., 2012). Thus, it possible 
that another process is responsible for their degradation, like ones known to degrade lysosomal 




Recently, a new cellular pathway responsible for selective lysosome membrane protein 
degradation was described in the model organism Saccharomyces cerevisiae called the ILF 
(intralumenal fragment) pathway: Immediately prior to homotypic fusion between vacuoles 
(yeast lysosomes), resident polytopic proteins are sorted into an area of membrane encircled by 
fusogenic lipids and proteins assembled in a ring at the vertex that forms the interface (or 
―boundary‖) between docked organelles (Wang et al., 2002; McNally et al., 2017). Upon lipid 
bilayer merger at the vertex ring, boundary membranes and the protein embedded in them are 
internalized as an intralumenal fragment that is then degraded by lumenal hydrolases. Although 
no membrane-associated proteins have been shown to be degraded by this pathway, it is feasible 
that they too can be sorted and entrapped in boundary membranes (Mattie et al., 2017), as the 
intermembrane distance between sandwiched membranes (8 nm) is wide enough to include 
proteins bound to the outer leaflets of the bilayers. Thus, I hypothesized that perhaps membrane-
associated proteins within complexes responsible for TOR signaling may be sorted and degraded 















MATERIALS AND METHODS 
 
Yeast strains and reagents 
Strains listed in Table 1 areSaccharomyces cerevisiaeused in this study. All yeast cultures were 
grown at 30ºC in YPD media (1% yeast extract, 2% peptone, 2% dextrose), or synthetic 
complete minimal media (SC, 0.67% yeast nitrogen base, 2% dextrose, amino acids and vitamins 
as needed), unless otherwise indicated. Liquid cultures were grown with rotary agitation at 200 
rpm for aeration, and 1% agar was added to the medium for colony growth on plates. 
Biochemical and yeast growth reagents used are acquired from either Sigma-Aldrich, Invitrogen 
or BioShop Canada Inc. Fusion reactions reagents used were prepared in 20 mM Pipes-KOH, pH 
6.8, and 200 mM sorbitol (Pipes Sorbitol buffer, PS).  
 
Fluorescence microscopy 
Images presented in this study were captured using a Nikon Eclipse TiE inverted microscope 
equipped with a motorized laser TIRF illumination unit, Photometrics Evolve 512 EM-CCD 
camera, CFI ApoTIRF 1.49 NA 100x objective lens, and 488 nm or 561 nm (50 mW) solid-state 
lasers operated with Nikon Elements software. The brightness and contrast, inversion and 
sharpness of images shown were adjusted using ImageJ Software. ImageJ was also used to 
generate Fluorescence intensity profiles of GFP fluorescence. 
 
FM4-64 was used to stain live yeast cells to label vacuole membranes and prepared for 
imaging using a pulse-chase method as previously described (Brett et al., 2008). 0.4 ml of a seed 
culture grown overnight in SC medium at 30ºC was added to 4ml of YPD medium containing 0.5 
µl of a 5 mM FM4-64 stock in DMSO (50 µM final), then grown for 1 hour at 30ºC to allow 
cellular dye uptake. Afterwards, cells were pelleted at 4500 rpm for 1 minute, washed with 1 ml 
SC medium, resuspended in 3 ml SC medium, and grown for another 1-2 hours at 30ºC before 
imaging, allowing the accumulation of dye in vacuole compartments. For isolated vacuole 
imaging, 0.5 µl of FM4-64 stock was added to freshly isolated vacuoles, which were then 
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incubated at 27ºC for 10 min., and placed on ice prior to imaging, as in Wang et al. (2002). 
Preparing samples for the rapamycin treatment, live cells were treated with 7 μM rapamycin for 
120 minutes at 30 °C after first hour of FM4-64 staining. Time-lapse videos were captured using 
a Chamlide TC-N incubator (Live Cell Instruments) at 30 °C with cells plated on coverslips 
coated with concavalin-A (1 mg/ml in 50 mM HEPES, pH 7.5, 20 mM calcium acetate, 1 mM 
MnSO4). 
 
Vacuole isolation and homotypic vacuole fusion 
Vacuoles were isolated from yeast cells used the protocol previously described (Haas, 1995). 
Yeast cells were spheroplasted with Lyticase and centrifuged for 90 min. at 125,000 g on a 
15/8/4/0% Ficoll® (GE Healthcare) gradient dissolved in PS buffer (20 mM Pipes-KOH pH 6.8, 
200 mM Sorbitol). Isolated vacuoles were obtained from the 4%/0% interface, and quantified 
using the Bradford assay (Thermo Scientific), based on Bradford (1976). 6 μg of vacuoles 
isolated from GFP derivative strains were used in fusion reactions in standard fusion reaction 
buffer with 0.125 M KCl, 5 mM MgCl2, 1 mM ATP and 10 μM CoA. FM4-64 was used to stain 
membrane of isolated vacuoles by treating vacuoles with 3 μM FM4-64 for 10 minutes at 27 °C. 
Reactions were incubated at 27 °C for 60 minutes, unless otherwise noted, and placed on ice 
prior to visualization by HILO microscopy. For rapamycin treatment, isolated vacuoles were 
pretreated for 15 minutes at 27 °C with 7 μM Rapamycin, then incubated for another 30 minutes.  
 
Western blot analysis 
Isolated vacuoles from yeast strains expressing a GFP-tagged vacuolar membrane protein was 
used for sample preparation. Fusion reactions were prepared as previously described. Samples 
were incubated for 0 (ice), or 60 minutes at 27 °C. After incubation, protease inhibitors (6.7 μM 
leupeptin, 33 μM pepstatin, 1 mM PMSF and 10.7 mM AEBSF), 1% DDM and 5X laemmli 
sample buffer were added. Samples were probed for α-GFP (Abcam, Cambridge, UK). All 
samples were repeated at least two times. GE Amersham Imager 600 was to acquire the images 
of blots by chemiluminescence. The acquired images were then edited and prepared using Adobe 
Photoshop and Illustrator CC software. 
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Data analysis and presentation 
To ensure the reliability of data, both biological replicate and technical replicate were taken into 
account. Each experiment was repeated at least twice on different days (biological replicate) and 
a great number of micrographs were taken (n>20) for each GFP strain to ensure unbiasedness 
(technical replicate). For cumulative probability calculations, 50 vacuoles were used for each 
strain (n=50). For the purpose of quantitating isolated vacuole micrographs, I calculated the 
relative boundary membrane or lumenal GFP fluorescence using only docked vacuoles by 
measuring their surface area, the length of the boundary. Using ImageJ software, measurements 
of GFP fluorescence intensities were measured using a ROI 4x4 pixels in diameter and acquiring 
a fluorescence value on the outer vacuole membrane, within the lumen and on the boundary 
membrane. Data are reported as mean ± SEM. Student T-test is used the test the significance the 
data compared to control Vph1-GFP.  Quantitative data was acquired using ImageJ software. 
















Table 1. List of yeast strains used in this study 










Huh et al., 2003 
Huh et al., 2003 











Huh et al., 2003 
Huh et al., 2003 
Huh et al., 2003 
Huh et al., 2003 
Huh et al., 2003 
Vph1-GFP BY4741, Vph1-GFP::HIS3MX Huh et al., 2003 

















EGO complex proteins Ego1 and Ego3 are sorted into the ILF pathway for degradation in live 
yeast cells 
To test this hypothesis, I studied baker’s yeast (Saccharomyces cerevisiae) and its vacuolar 
lysosome as models by examining the sorting, internalization and degradation of six different 
GFP-tagged components of TORC1 (Tco89, Kog1), EGO (Ego1, Ego3), SEACIT (Iml1) or 
SEACAT (Sea3) complexes during homotypic fusion events (see Figure 1). First, I studied live 
yeast cells grown to mid-log phase in rich medium (when TOR signaling is expected to be 
activated) using HiLo microscopy and examined the distribution of the GFP-tagged proteins on 
vacuole membranes stained with FM4-64 (Figure 2A). I found that all GFP-tagged proteins 
examined were sorted into boundary membranes with the exception of Kog1-GFP, a component 
of TORC1, which primarily localized to puncta adjacent to vacuole membranes, likely 
representing endosomal compartments.  
 
ILF client proteins are recognized and actively sorted in to boundary membranes, and as 
such, must be enriched with boundary membranes. It is apparent when I first looked the FI plots 
(Figure 2A). Then I conducted line scan analysis (Figure 2B) to determine if any of the protein of 
my interest is an ILF client (i.e. enriched in the boundary). If proteins were enriched in the 
boundary, the intensity of GFP signal (represented by the peak of the blue curve in the graph) 
would be more than that of the FM4-64 signal (represented by the red curve). The line scan 
analysis suggests Ego1-GFP is enriched as the other proteins are uniformly distributed. Ego3-
GFP also seems to be enriched although its not very clear. To further determine which TOR 
signaling proteins were ILF clients, I compared their distributions to those observed for Vph1-
GFP, the stalk domain of the V-type H
+
-ATPase protein complex that is known to be uniformly 
distributed on vacuole membranes, and Fet5-GFP, a membrane-bound iron/copper oxidase that is 
known to be excluded from boundary membranes (Wang et al., 2002; McNally et al., 2017). I 
expected that GFP-tagged proteins with significantly higher boundary fluorescence values than 
these proteins to be ILF clients. I found that, as compared to GFP-tagged Vph1 or Fth1, only 
boundary fluorescence of GFP-tagged EGO complex subunits Ego1 and Ego3 were higher 
(Figure 2C), confirming enrichment in boundary membranes suggesting that they are 
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constitutively degraded by the ILF pathway under unstimulated conditions in yeast cells 
collected from a culture growth to mid-log phase. Of the remaining proteins studied (besides 
Kog1-GFP), only Tco89 showed enough membrane fluorescence for subsequent reliable 
micrographic analysis. Although a small number of Tco89 shows enrichment in the boundary 
membrane (Figure 2A), its average distribution on two fusing vacuoles is more like that of Fet5-
GFP (Figure 2B). This observation suggests Tco89 is not as actively sorted into the boundary 
membrane as Ego1 and Ego3.   
 
Upon fusion, polytopic proteins embedded in boundary membranes should be 
internalized into the lumen. To confirm, I calculated Ego1-GFP, Ego3-GFP and Tco89-GFP 
lumenal fluorescence values and found that they were significantly higher than Vph1-GFP and 
Fet5-GFP (Figure 2D), again supporting that these proteins were internalized into the vacuole 
lumen by the ILF pathway. To confirm, I recorded vacuole fusion events with live yeast cells and 
found that Ego1-GFP and Ego3-GFP decorated ILFs formed during vacuole fusion (Figure 2E). I 
exclusively studied Ego1-GFP and Ego3-GFP as the FI of Tco89-GFP was too low for live cell 
video. I found that both protein is indeed internalized into the vacuolar lumen by forming 
intralumenal fragments during membrane fusion events over time (Figure 2E). This result is even 
more apparent when comparison is made with Vph1-GFP, a protein known to be degraded by the 
ILF pathway. Thus, I conclude that GFP-tagged Ego1 and Ego3, subunits of the EGO complex, 
seem to be clients of the ILF pathway that are constitutively turned over in unstimulated, actively 
growing cells. Furthermore, these results are the first to suggest that the ILF pathway may also 
degraded membrane-associated proteins as well as polytopic proteins. 
 
EGO complex protein Ego3 is sorted into the ILF pathway in vitro 
All of the molecular machinery underling the ILF pathway should copurify with isolated 
vacuoles, allowing further biochemical characterization in vitro (McNally et al., 2017). Thus, if 
Ego1 and Ego3 are degraded by the ILF pathway, then I reasoned that this process should be 
recapitulated in vitro. After isolating vacuoles, initiating fusion in vitro and examining GPF 
localization, I confirmed that Ego3-GFP is sorted into boundary membranes during homotypic 
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vacuoles fusion in vitro (Figure 3A). However, all other proteins studied, including Ego1-GFP, 
localized to puncta adjacent to vacuole membranes, resembling endosomal compartments 
(Figure 3A). These results were not entirely unexpected, as TOR signaling complex localization 
is known to be responsive to cytoplasmic amino acid or nutrient levels (González and Hall, 
2017). Removing these organelles from the cytoplasm (and nutrients) likely mimics nutrient 
depravation, which has been shown to shunt TOR components from vacuole/lysosome to 
endosome membranes, to supposedly shut off TOR signaling (Hailey et al., 2010).  
 
Because it continued to localize to boundary membranes, I further investigated Ego3-
GFP internalization by recording its vacuole distribution over the course of the fusion reaction in 
vitro. I observed Ego3-GFP is indeed internalized into the lumen of fusing vacuoles over time 
(Figure 3B). I then confirmed that Ego3-GFP was found in boundary membranes and 
accumulated in the lumen of vacuoles over the course of the fusion reaction by calculating the 
GFP fluorescence of Ego3-GFP over time within the lumen relative to the total fluorescence 
(Figure 3C). Maximum lumenal fluorescence was observed at 30 minutes, as it seemed to 
decrease afterwards (at 60 minutes). This loss of signal is likely a product of GFP protein 
degradation in the vacuole, accounting for the observed loss of signal. Regardless, based on these 
results, I conclude that, unlike other TOR signaling proteins, Ego3 downregulation may not 
involve relocation to endosome membranes (possibly in response to changing cytoplasmic 
nutrient levels), but rather is mediated by sorting into the ILF pathway for degradation. 
 
Ego3 degradation by the ILF pathway is stimulated by the TOR inhibitor rapamycin 
Having established that the ILF pathways can contribute to TOR signal protein downregulation 
under unstimulated conditions, I next determined whether it also mediates protein degradation 
when TOR signaling is inactivated by the inhibitor rapamycin. First, using HiLo microscopy, I 
examined the distribution of the GFP-tagged TOR proteins on vacuole membranes after 7 μM 
rapamycin treatment in living cells and in vitro (Figure 4A). The concentration of rapamycin I 
used in this study was used in another study of our lab (McNally and Brett, 2017) where no 
growth abnormality was observed. In live cells, I found that all GFP-tagged proteins were found 
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in boundary membranes, including Kog1-GFP, which was found on puncta – presumably 
representing endosomal compartments – in untreated cells (see Figure 2A), suggesting that 
perhaps upon activation, all TOR proteins could be degraded by this pathway. However, when I 
examined isolated vacuoles, I found that only Ego1-GFP and Ego3-GFP are enriched in 
boundary membranes after rapamycin treatment (Figure 4A and B). Other TOR proteins 
continue to localize to endosomal compartments, as observed in the absence of rapamycin 
(Figure 2A), suggesting that rapamycin does not drive the relocation of these proteins to vacuole 
membranes for degradation by the ILF pathway. An alternatively explanation is that rapamycin 
perhaps cannot override TOR relocation to endosomes in response to nutrient withdrawal, which 
is consistent with the interpretation that TOR is inactive on endosome membranes. 
 
In the case of GFP-tagged Ego3, which seems to be constitutively degraded by the ILF 
pathway, I found that rapamycin treatment significantly increased boundary enrichment (Figure 
4B) and lumenal fluorescence (Figure 4C), suggesting that TOR inhibition does indeed drive its 
degradation. Moreover, this response was selective to Ego3-GFP, as Vph1-GPF and Fet5-GPF 
degradation by the ILF pathway was unaffected by rapamycin treatment (Figure 4A – C). Finally, 
to demonstrate that Ego3-GFP protein degradation was stimulated by rapamycin treatment, I 
assessed GFP cleavage from Ego3-GFP by western blot analysis (Figure 4D). I found that more 
GFP was cleaved from Ego3 after TOR inactivation by rapamycin, supporting the conclusion 
that TOR inactivation by rapamycin stimulates Ego3 degradation by the ILF pathway. All things 
considered, these results show that the ILF pathway contributes to TOR signaling protein 











In this study, I demonstrate with confidence that GFP-tagged Ego3, and possibly other 
components of TOR signaling protein complexes, is sorted into ILFs for degradation upon fusion 
of two vacuoles both in vivo and vitro. This seems to mediate constitutive turnover of Ego3 and 
is stimulated when TOR signaling was inhibited by rapamycin. Whereas other TOR signaling 
proteins studies are downregulated through relocalization to endosome membranes as previously 
reported. Why Ego3 downregulation differs from other proteins in this pathway, how this study 
improves our understanding of the ILF pathway, and possible physiological relevance in context 
tot longevity is discussed. 
 
New mechanism for TORC1 inhibition 
Since TORC1 is an important protein complex for regulating cell growth and metabolism, it is 
crucial to understand what regulate TORC1 itself. So far, there are three major ways that TORC1 
can be regulated: through dephosphorylation of Sch9 (substrate of TORC1), EGO complex and 
feedback loop/ribosome biogenesis homeostasis (Loewith and Hall, 2011). Although the detail 
mechanism is different, these elements all regulate TORC1 in the same way, by activation or 
inhibition. Inhibition of TORC1 has major consequences on cell growth and metabolism. When 
TORC1 is inhibited, protein synthesis and ribosome biogenesis are greatly reduced. Stress 
responses, which are normally inhibited by TORC1, are active when TORC1 is turned off.  
Furthermore, nutrient uptake is also reduced when TORC1 is inhibited (Loewith and Hall, 2011). 
Knowing that TORC1 inhibition is responsible for regulating many cellular processes, what are 
some ways that TORC1 can be inhibited? Nitrogen starvation is a way that can inhibit TORC1 
activity by reduction of Sch9 phosphorylation. Another way is using Rapamycin, a known TOR 
inhibition that mimics nitrogen starvation. Moreover, TORC1 regulator EGO complex can 
trigger its inhibition. In this study, I demonstrate the degradation of components of EGO, 
TORC1, and SEA complex directly by the ILF pathway might be another way the cell regulates 
TORC1 activity through inhibition. In my experiments, I observed Ego3 is degraded at a higher 
level compared to control when the cell is under rapamycin treatment, which mimics cellular 
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starvation. This result suggests that in response to starvation, the cell uses the ILF to degrade the 
components of the EGO, TORC1, and SEA, therefore downregulating TORC1 activity.    
Although most components of EGO, TORC1 and SEA complex I studied is shown to be 
degraded in vivo, I find all of these components except Ego3-GFP is concentrated in endosomal 
compartments when studied in vitro. Previous studies suggest when components of TORC1 is 
inactive, they are sorted into endosomal compartments (Chiang et al., 2010). By isolating the 
vacuoles, these TORC1 components might be rendered inactive therefore sorted into endosomal 
compartments. There must be an important reason why Ego3-GFP is spared from this sorting 
process. So what is Ego3 and why is it important? Ego3 is a subunit of the EGO complex. This 
complex is located on the endosomal and vacuolar membranes and composed of Gtr1, Gtr2, 
Ego1, and Ego3 subunits. It has a crucial role in cell growth and autophagy regulation through 
relaying amino acid signals to activate TORC1 (De Virgilio et al., 2009). It was shown that Ego3 
assumes a homodimeric structure similar to that of the mammalian MP1-p14 heterodimer and the 
C-terminal domains of the yeast Gtr1-Gtr2 heterodimer, both of which function in TORC1 
signaling. This unique homodimer conformation of Ego3 is required for its binding to Ego1 and 
its recruitment to the vacuolar membrane. Furthermore, the Ego3 also has a binding site for Gtr1-
Gtr2, suggesting it is an important mediator for docking of the Gtr GTPases to the vacuolar 
anchor Ego1 (Zhang et al., 2012). These finds suggest Ego has a scaffolding role within the EGO 
complex that is important for its regulatory function.  However, it’s worthy to note Ego3 also 
participate in other cellular processes. For example, it was shown that Ego3, also known as Slm4, 
also participate in endosomal-vacuolar trafficking of plasma membrane proteins (Wuttke et al., 
2012). Although there are redundant proteins that perform endosomal-vacuolar trafficking such 
as Rcr2 and Vps20 (Wuttke et al., 2012), it is worthy in the future to study how Ego3 
degradation by the ILF pathway affects endosomal-vacuolar trafficking. For purpose of further 
investigation of the regulation of TORC1 signaling by the ILF pathway, it is worthy to delete 
Ego3 to observe the effect of this deletion on TORC1 signaling. Moreover, cycloheximide, a 
known activator of TOR signalling (Hall et al., 2011), could be applied to isolated vacuoles to 






ILF pathway also degrades soluble cytosolic proteins   
Prior to this study, only polytopic proteins are shown to be degraded by the ILF pathway. For 
example, Fth1, an iron transporter that is embedded in the vacuolar membrane, was shown to be 
degraded by the ILF pathway (McNally and Brett, 2017). Here I show that the ILF pathway 
might also degrade cytoplasmic proteins if they are membrane soluble. Ego3 is a membrane 
soluble protein that has no transmembrane domain. It is has a very small size of 18 kDa (Zhang 
et al., 2012). In this study, I show that ILF pathway is able to degrade such protein. When two 
vacuoles are fusing, the distance between membranes at the contact zone is only around eight nm. 
Thus, a bulky protein is unlike to enter this confined space. Therefore, I speculate in order for a 
membrane soluble protein to be degraded by the ILF pathway, it has to be satisfy certain size 
requirement.  
 
Another interesting conclusion can be made from the fact that ILF degrades membrane 
soluble proteins such as Ego3. Since the protein is membrane soluble, meaning it is the on the 
cytosolic side of the vacuolar membrane, the sorting machinery for ILF pathway must also be on 
the cytosolic side of the membrane. Then what is the mechanism behind the sorting of 
components of EGO, TORC1 and SEA for degradation by the ILF pathway? Although I did not 
investigate the mechanism in this study, a previous study done by our laboratory suggests a 
molecular sieving mechanism is involved (McNally et al., 2017). More precisely, this study 
suggests a ubiquitin-based mechanism is involved in the sorting for proteins into the ILF 
pathway (Figure 5). Ubiquitin is a highly conserved and ubiquitously expressed small protein 
composed of 76 amino acids. The first step of labeling involves the attachment of ubiquitin to a 
target protein. This process involves three important enyzmes: the ubiquitin activating enzyme or 
E1 enzyme, the ubiquitin conjugating enzyme or E2 enzyme, and the ubiquitin ligase or E3 
ligase. In the case of ILF pathway, evident suggests Sna4 is an important mediator protein for the 
target protein and ubiquitin ligase.If ubiquitylation mediates degradation, labeled proteins must 
be recognized at the vertex ring for sorting into the ILF pathway and these three important 
proteins containing partial potential ubiquitin binding domains (UBDs) are involved: Vps11, 
Vps18, and Vps39 (Nickerson et al., 2009). These proteins along with three other subunits form 
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HOPS, the lysosomal multisubunit tethering complex important for MVB-lysosome and 
homotypic lysosome fusion (Balderhaar and Ungermann, 2013). HOPS is an important mediator 
for multiple fusion events at the yeast vacuole, including homotypic vacuole fusion, which is 
important for the ILF pathway. For future studies, in order to understand better the degradation 
of Ego3, it is worthy to investigate the exact mechanism behind its labeling. 
 
Physiological relevance  
It is known TORC1 is a nutrient sensor and growth controller that plays an essential role in aging. 
One of mechanism that Tor controls nutrient level in the cell is changing nutrient transporter 
expression on the lysosomal membrane (McNally and Brett, 2017). Since the ILF pathway both 
degrades lysosomal nutrient transports and components of TORC1 and its regulators, the 
degradation pathway might play a mediator role between nutrient availability and aging. The 
pathway could control cell growth by changing the availability of nutrient transporters on the 
vacuolar membrane following TORC1 signalling. Although speculative at this point, it is worthy 
to further investigate the involvement of the ILF pathway in aging in the future. 
 
 Cancers are very common aging disorders. Many types of cancers increase significantly 
with age since aging has many negative effects on cellular processes including metabolism and 
waste disposal. For example, prostate cancers are the most frequent cancer in older males 
compared to younger males (Hsing et Chokkalingam, 2006). As for older females, breast cancers 
are the most frequent compared to younger females (Gaffield et al., 2009). Since ILF could 
participate in regulation of cellular aging, it is possible to speculate it could be a potential target 
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Figure 1. Overview of TORC1 signaling in S.cerevisiae. The proteins of interest of this study 

























Figure 2. Components of EGO, TORC1 and SEA complex are constitutively degraded by 
ILF pathway in vivo 
(A) Micrographs of in vivo yeast cells expressing six different GFP-labeled components of EGO, 
TORC1 and SEA complex illustrating their presence at the boundary of two fusing vacuoles 
except Kog1-GFP. GFP fluorescence intensity profile plots (left panel). Scale bars, 1 μm. (B) 
Line-scan analysis of GFP-labeled proteins shown in A along dotted line illustrating GFP (blue) 
or FM4-64 (red) fluorescence distribution. (C) Cumulative probability curves of GFP 
fluorescence intensity within the boundary membrane (relative to outside) for Ego1-GFP, Ego3-
GFP and Tco89-GFP in vivo (D) Cumulative probability curves of lumenal GFP fluorescence 
intensity of of Ego1-GFP, Ego3-GFP and Tco89-GFP in vivo. When compared to Vph1-GFP 
using student t-test (t <0.05), the lumenal fluorescence of Ego1-GFP (t=6.28 x 10
-8
) and Ego3-
GFP (t=0.004) are significant higher. (E) Images captured from in vivo time-lapse videos of live 
yeast cells undergoing vacuole fusion, expressing Ego1-GFP, Ego3-GFP or Vph1-GFP stained 






















Figure 3. Ego3-GFP is constitutively degraded by ILF pathway in vitro 
(A) Micrographs of in vitro yeast cells expressing six different GFP-labeled components of EGO 
complex, TOR1 complex and SEA complex. Only Ego3-GFP is present at the boundary of two 
fusing vacuoles. The other GFP labeled proteins are concentrated in puncta. GFP fluorescence 
intensity profile plots (left panel). Scale bars, 1 μm. (B) Images captured from in vitro time-lapse 
videos of isolated vacuoles undergoing vacuole fusion, showing internalization of Ego3-GFP 
into the lumen of two fusing vacuoles. (C) Cumulative probability curves of lumenal GFP 
fluorescence intensity of isolated vacuoles containing Ego3-GFP measured after 0, 15, 30, 60 
minutes. When compared to Vph1-GFP using student t-test (t <0.05), the lumenal fluorescence 
of Ego3-GFP (3.42x10
-6



























Figure 4. The effect of Rapamycin on degradation of components of TORC1, EGO and 
SEA complex in vivo and in vitro 
(A) Micrographs of in vivo and in vitro yeast cells expressing six different GFP-labeled 
components of EGO, SEA and TORC1 complex in the presence of Rapamycin. GFP 
fluorescence intensity profile plots (left panel). Scale bars, 1 μm. (B) Cumulative probability 
curves of GFP fluorescence intensity within the boundary membrane (relative to outside) for 
Ego3-GFP in the presence of Rapamycin in vitro. Bar graph showing average boundary fluoresce 
intensity of Ego3-GFP in the absence or presence of Rapamycin. (C) Cumulative probability 
curves of lumenal GFP fluorescence intensity of Ego3-GFP in vitro. Bar graph showing average 
lumenal fluoresce intensity of Ego3-GFP in the absence or presence of Rapamycin. When 
compared to Ego3-GFP under no rapamycin treatment using student t-test (t <0.05), the lumenal 
fluorescence of Ego3-GFP under rapamycin treatment (t=1.19 x 10
-4
) is significant higher. (D) 































Figure 5. Proposed labeling and sorting of EGO complex by the ILF pathway. Following 
Tor inactivation, E3 ligase, with the help of a possible adaptor protein Sna4, labels Ego3 with 
ubiquitin. Once ubiquitinylated, Ego complex is recognized and sorted into the boundary of two 
fusing vacuoles by UBDs (not shown here) for degradation by the ILF pathway.    
